Cartesian Therapeutics, Inc.
$6.94
▼
-2.03%
2026-04-21 09:11:00
www.cartesiantherapeutics.com
NGM: RNAC
Explore Cartesian Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$183.97 M
Current Price
$6.94
52W High / Low
$15.57 / $5.6
Stock P/E
—
Book Value
$-4.85
Dividend Yield
—
ROCE
-30.8%
ROE
195.88%
Face Value
—
EPS
$-5.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
75
Beta
0.56
Debt / Equity
-0.1
Current Ratio
8.65
Quick Ratio
8.65
Forward P/E
-3.54
Price / Sales
56.68
Enterprise Value
$46.06 M
EV / EBITDA
-0.55
EV / Revenue
16.47
Rating
Strong Buy
Target Price
$35.57
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 2. | Bone Biologics Corporation | $1.38 | — | $2.5 M | — | -60.16% | -70.17% | $6.75 / $1.05 | $3 |
| 3. | Exelixis, Inc. | $46.57 | 16.78 | $11.84 B | — | 36.6% | 35.53% | $49.62 / $33.76 | $8.23 |
| 4. | Revelation Biosciences, Inc. | $1.16 | — | $4.32 M | — | -94.64% | -1.31% | $43.48 / $0.99 | $5.59 |
| 5. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 6. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 7. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.95 M | 0.45 M | 0.3 M | 1.1 M | -0.76 M | — |
| Operating Profit | -21.94 M | -21.07 M | -21.81 M | -21.89 M | -19.15 M | — |
| Net Profit | -92.58 M | -35.9 M | 15.89 M | -17.71 M | -10.25 M | — |
| EPS in Rs | -3.49 | -1.35 | 0.6 | -0.67 | -0.39 | -1.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.8 M | 38.91 M | 26 M | 110.78 M |
| Operating Profit | -86.7 M | -36.32 M | -85.71 M | 14.54 M |
| Net Profit | -130.3 M | -77.42 M | -219.71 M | 35.38 M |
| EPS in Rs | -4.92 | -2.92 | -8.29 | 1.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 296.41 M | 435.02 M | 305.05 M | 165.89 M |
| Total Liabilities | 422.65 M | 441.82 M | 745.23 M | 72.06 M |
| Equity | -126.24 M | -6.8 M | -440.18 M | 93.83 M |
| Current Assets | 129.28 M | 216.63 M | 90.73 M | 148.14 M |
| Current Liabilities | 14.94 M | 22.98 M | 68.21 M | 25.08 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -73.94 M | -23.67 M | -51.16 M | -31.63 M |
| Investing CF | -5.45 M | -8.74 M | 34.61 M | -15 M |
| Financing CF | -8.05 M | 168.43 M | -13.14 M | 39.22 M |
| Free CF | -79.39 M | -32.77 M | -51.37 M | -32.83 M |
| Capex | -5.45 M | -9.09 M | -0.21 M | -1.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 49.64% | -76.53% | — | — |
| Earnings Growth % | 64.76% | -721.02% | — | — |
| Profit Margin % | -198.97% | -844.91% | 31.94% | — |
| Operating Margin % | -93.33% | -329.59% | 13.12% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -195.27% | -903.84% | 35.29% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-05 | 1:0.0333333 |